Levetiracetam-induced leukocytoclastic vasculitis
- PMID: 28458437
- PMCID: PMC5351226
- DOI: 10.4103/0253-7613.201020
Levetiracetam-induced leukocytoclastic vasculitis
Abstract
Drug-induced leukocytoclastic vasculitis is a small-vessel vasculitis that most commonly manifests with palpable purpuric lesions on gravity-dependent areas. Vasculitis occurs within weeks after initial administration of medication and demonstrates clearance upon withdrawal of medication. Levetiracetam, a pyrrolidone derivative, is used as an adjunctive therapy in patients with refractory focal epilepsy, myoclonic epilepsy, and primary generalized tonic-clonic seizures. We present a case of a 14-year-old female, who developed cutaneous small-vessel vasculitis within 8 days of initiation of levetiracetam. Vasculitis was successfully managed by discontinuation of medication and systemic corticosteroids. This adverse reaction, to the best of our knowledge, has not been previously reported in literature.
Keywords: Cutaneous small-vessel vasculitis; drug-induced leukocytoclastic vasculitis; immune complex; levetiracetam.
Conflict of interest statement
There are no conflicts of interest.
Figures
References
-
- Merkel PA. Drug-induced vasculitis. Rheum Dis Clin North Am. 2001;27:849–62. - PubMed
-
- Fiorentino DF. Cutaneous vasculitis. J Am Acad Dermatol. 2003;48:311–40. - PubMed
-
- Litt JZ. Drug Eruption Reference Manual. 12th ed. London: Taylor and Francis; 2006. pp. 655–6.
-
- Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49:2229–32. - PubMed
-
- Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45. - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
